In vitro effect of eltrombopag alone and in combination with azacitidine on megakaryopoiesis in patients with myelodysplastic syndrome

Abstract Thrombocytopenia is a severe complication for patients with myelodysplastic syndrome (MDS). Eltrombopag increases platelet count in MDS patients but its combination with azacitidine elicited controversial results. We aimed to quantify the colony forming units of megakaryocytes (CFU-Mk) obtained from CD34+ bone marrow cells isolated from patients with MDS and from healthy donors that were cultured in vitro in the presence or absence of azacitidine and with or without the sequential addition of eltrombopag to the culture medium. CD34+ bone marrow cells from 6 MDS patients and 3 controls were expanded in vitro and cultured for 3 days with or without azacitidine. Subsequently, a CFU-Mk assay was performed in presence or absence of eltrombopag. The addition of eltrombopag in the CFU-Mk assay after mock treatment of CD34+ cells increased the number of CFU-Mk in both controls and patients. On the contrary, using azacitidine pretreated CD34+ cells, eltrombopag minimally increased CFU-Mk in controls and produced heterogeneous response in MDS patients with no change in two patients and CFU-Mk increase in four patients. In vitro CFU-Mk assay suggest that some MDS patients are likely to benefit from the sequential addition of eltrombopag after azacitidine treatment, in the context of a personalized medicine.

[1]  M. Konopleva,et al.  A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure , 2019, Leukemia & lymphoma.

[2]  A. Verma,et al.  Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia. , 2018, Blood.

[3]  M. Mittelman,et al.  Thrombocytopenia in Patients with Myelodysplastic Syndromes: Still an Unsolved Problem , 2018, Mediterranean journal of hematology and infectious diseases.

[4]  K. Kreuzer,et al.  Thrombopoietin mimetics for patients with myelodysplastic syndromes. , 2017, The Cochrane database of systematic reviews.

[5]  A. Stamatoullas,et al.  Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. , 2017, The Lancet. Haematology.

[6]  D. Kaplan,et al.  Revealing eltrombopag’s promotion of human megakaryopoiesis through AKT/ERK-dependent pathway activation , 2016, Haematologica.

[7]  S. Kambhampati,et al.  Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies , 2016, Leukemia.

[8]  K. Götze,et al.  Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. , 2015, The Lancet. Haematology.

[9]  Lei Yang,et al.  Low-dose decitabine promotes megakaryocyte maturation and platelet production in healthy controls and immune thrombocytopenia , 2015, Thrombosis and Haemostasis.

[10]  S. E. Jacobsen,et al.  A pilot phase I dose finding safety study of the thrombopoietin‐receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine , 2014, European journal of haematology.

[11]  C. Mitsiades,et al.  Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. , 2012, Blood.

[12]  E. Vellenga,et al.  Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme , 2011, British journal of haematology.

[13]  M. Voso,et al.  Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine. , 2011, Leukemia research.

[14]  H. Papadaki,et al.  Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome. , 2011, Leukemia research.

[15]  Giuseppe Leone,et al.  Analysis of genome-wide methylation and gene expression induced by 5-aza-2′-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia , 2010, Leukemia & lymphoma.

[16]  M. Kawahara,et al.  Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. , 2009, Blood.

[17]  J. Luengo,et al.  Preclinical Activity of Eltrombopag (SB-497115), an Oral, Nonpeptide Thrombopoietin Receptor Agonist , 2009, Stem cells.

[18]  F. D'Alo',et al.  Epigenetic Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemias , 2008, Current medicinal chemistry.

[19]  N. Shinton.  WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues , 2007 .

[20]  C. Ho,et al.  Circulating Levels of Thrombopoietic and Inflammatory Cytokines in Patients with Acute Myeloblastic Leukemia and Myelodysplastic Syndrome , 2002, Oncology.

[21]  J. Visvader,et al.  Megakaryocytic differentiation induced in 416B myeloid cells by GATA-2 and GATA-3 transgenes or 5-azacytidine is tightly coupled to GATA-1 expression. , 1993, Blood.

[22]  A. Nagler,et al.  Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial. , 2018, The Lancet. Haematology.

[23]  W. Vainchenker,et al.  Growth and differentiation of the human megakaryoblastic cell line (ELF-153): a model for early stages of megakaryocytopoiesis. , 1994, Blood.